Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial

PURPOSE: To compare intravitreal nesvacumab (anti-angiopoietin-2) + aflibercept vs intravitreal aflibercept injection (IAI) in neovascular age-related macular degeneration (nAMD). METHODS: Eyes were randomized (1:2:3) to nesvacumab 3 mg + aflibercept 2 mg (LD combo), nesvacumab 6 mg + aflibercept 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Heier, Jeffrey S., Ho, Allen C., Boyer, David S., Csaky, Karl, Vitti, Robert, Perlee, Lorah, Chu, Karen W., Asmus, Friedrich, Leal, Sergio, Zeitz, Oliver, Cheng, Yenchieh, Schmelter, Thomas, Brown, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Manuscripts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954160/
https://www.ncbi.nlm.nih.gov/pubmed/37008402
http://dx.doi.org/10.1177/24741264221126061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954160/
https://www.ncbi.nlm.nih.gov/pubmed/37008402
http://dx.doi.org/10.1177/24741264221126061

Ejemplares similares